###begin article-title 0
###xml 59 81 59 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH, LOC387715/HTRA1, </italic>
Neovascular Age-Related Macular Degeneration Risk Based on CFH, LOC387715/HTRA1, and Smoking
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 280 299 280 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">complement factor H</italic>
###xml 301 304 301 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 312 321 312 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
###xml 331 336 331 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
Age-related macular degeneration (AMD) is the major cause of blindness in the elderly. Those with the neovascular end-stage of disease have irreversible loss of central vision. AMD is a complex disorder in which genetic and environmental factors play a role. Polymorphisms in the complement factor H (CFH) gene, LOC387715, and the HTRA1 promoter are strongly associated with AMD. Smoking also contributes to the etiology. We aimed to provide a model of disease risk based on these factors.
###end p 2
###begin title 3
Methods and Findings
###end title 3
###begin p 4
###xml 30 33 30 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 38 53 38 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
###xml 298 301 298 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 306 321 306 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
###xml 511 514 511 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 601 616 601 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
###xml 85 93 <span type="species:ncbi:9606">patients</span>
###xml 818 826 <span type="species:ncbi:9606">Patients</span>
We genotyped polymorphisms in CFH and LOC387715/HTRA1 in a case-control study of 401 patients with neovascular AMD and 266 controls without signs of disease, and used the data to produce genetic risk scores for the European-descent population based on haplotypes at these loci and smoking history. CFH and LOC387715/HTRA1 haplotypes and smoking status exerted large effects on AMD susceptibility, enabling risk scores to be generated with appropriate weighting of these three factors. Five common haplotypes of CFH conferred a range of odds ratios (ORs) per copy from 1 to 4.17. Most of the effect of LOC387715/HTRA1 was mediated through one detrimental haplotype (carriage of one copy: OR 2.83; 95% confidence interval [CI] 1.91-4.20), with homozygotes being at particularly high risk (OR 32.83; 95% CI 12.53-86.07). Patients with neovascular macular degeneration had considerably higher scores than those without disease, and risk of blinding AMD rose to 15.5% in the tenth of the population with highest predicted risk.
###end p 4
###begin title 5
Conclusions
###end title 5
###begin p 6
An individual's risk of developing AMD in old age can be predicted by combining haplotype data with smoking status. Until there is effective treatment for AMD, encouragement to avoid smoking in those at high genetic risk may be the best option. We estimate that total absence of smoking would have reduced the prevalence of severe AMD by 33%. Unless smoking habits change or preventative treatment becomes available, the prevalence of AMD will rise as a consequence of the increasing longevity of the population.
###end p 6
###begin p 7
Anne Hughes and colleagues show that an individual's risk of developing age-related macular degeneration in old age can be predicted by combining haplotype data with smoking status.
###end p 7
###begin title 8
Editors' Summary
###end title 8
###begin title 9
Background.
###end title 9
###begin p 10
Age-related macular degeneration (AMD) is the leading cause of vision loss in the elderly. The macula is the central region of the retina, the tissue at the back of the eye that converts light into electrical messages and sends them to the brain. In the commonest form of AMD-"dry" AMD-the light-sensitive cells in the macula gradually die. In "wet" or "neovascular" AMD (one in 10 cases of AMD, but responsible for 90% of severe AMD-related blindness), abnormal blood vessels grow below the macula. Fluid leaking out of these vessels dislodges and damages the macula, after which loss of vision occurs rapidly. Both forms of AMD destroy the sharp central vision that is needed for reading and driving, leaving only dim, blurred images or a black hole at the center of vision. Neither form can be cured but with wet AMD the loss of vision can sometimes be slowed or halted if caught early by destroying the new blood vessels with laser surgery or a technique called photodynamic therapy or by blocking their formation by injecting special drugs into the eye.
###end p 10
###begin title 11
Why Was This Study Done?
###end title 11
###begin p 12
###xml 431 434 431 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 464 480 464 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1.</italic>
###xml 751 754 751 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 759 774 759 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
###xml 57 63 <span type="species:ncbi:9606">person</span>
###xml 555 561 <span type="species:ncbi:9606">people</span>
No-one knows what causes AMD but factors that increase a person's risk of developing the disease include increasing age, smoking, being white, and a family history of AMD. Recently, researchers have identified several "polymorphisms" (inherited DNA sequence variations that are common within populations) that are associated with AMD. These polymorphisms are in the complement factor H gene (the scientific symbol for this gene is CFH) and in a gene region called LOC387715/HTRA1. It would be useful to be able to use these risk factors to identify those people at the highest risk of developing neovascular AMD before the disease damages their vision. In this study, the researchers have investigated the association between AMD and polymorphisms in CFH and LOC387715/HTRA1 in more depth. They have then used this new information to build a model of AMD risk that should allow physicians to identify individuals at high risk of developing neovascular AMD.
###end p 12
###begin title 13
What Did the Researchers Do and Find?
###end title 13
###begin p 14
###xml 44 47 44 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 52 67 52 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
###xml 304 307 304 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 444 459 444 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
###xml 870 873 870 873 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 878 893 878 893 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
###xml 87 93 <span type="species:ncbi:9606">people</span>
###xml 333 339 <span type="species:ncbi:9606">people</span>
###xml 528 534 <span type="species:ncbi:9606">people</span>
###xml 559 565 <span type="species:ncbi:9606">people</span>
###xml 664 670 <span type="species:ncbi:9606">people</span>
###xml 956 962 <span type="species:ncbi:9606">people</span>
###xml 1050 1056 <span type="species:ncbi:9606">people</span>
The researchers catalogued polymorphisms in CFH and LOC387715/HTRA1 in several hundred people with and without neovascular AMD. From these data, they identified three haplotypes (sets of polymorphisms that are inherited as a unit; everyone inherits two copies of each haplotype, one from each parent) in CFH that were more common in people with AMD than in those without and two that were associated with a decreased risk of developing AMD. In LOC387715/HTRA1 they identified one particularly detrimental haplotype. Compared to people without this haplotype, people with one copy of the deleterious haplotype were three times as likely to develop neovascular AMD; people with two copies were thirty times as likely to develop AMD. Smoking history also had a large effect on susceptibility to AMD. The researchers then developed a simple AMD risk scoring system based on CFH and LOC387715/HTRA1haplotypes and smoking status. From this, they calculated that people with the lowest risk scores have a minimal risk of developing AMD whereas about 15% of people with the highest risk scores are likely to develop AMD.
###end p 14
###begin title 15
What Do These Findings Mean?
###end title 15
###begin p 16
###xml 266 272 <span type="species:ncbi:9606">people</span>
###xml 569 575 <span type="species:ncbi:9606">people</span>
###xml 744 752 <span type="species:ncbi:9606">patients</span>
These findings indicate that it is possible to predict an individual's risk of developing AMD in old age by examining a small number of haplotypes and asking about their smoking status. The model developed by the researchers needs to be validated in other groups of people and may have to be modified if other gene variants that affect the risk of AMD are identified. For now, the results of this research provide physicians with a way to identify those individuals at the highest genetic risk of developing AMD so that they can step up their efforts to persuade these people to avoid smoking. In the future, when effective long-term treatments for AMD become available, the scoring system could also help doctors decide which of their elderly patients should be monitored most intensively for the early signs of AMD so that they can be treated before their vision is irreversibly damaged.
###end p 16
###begin title 17
Additional Information.
###end title 17
###begin p 18
Please access these Web sites via the online version of this summary at .
###end p 18
###begin p 19
MedlinePlus provides links to information on  and an  (in English and Spanish)
###end p 19
###begin p 20
Pages on the US National Institutes of Health  site provides text and speech information about AMD
###end p 20
###begin p 21
The  and the  also provide information about AMD
###end p 21
###begin title 22
Introduction
###end title 22
###begin p 23
###xml 338 339 338 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b001">1</xref>
###xml 435 436 435 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b002">2</xref>
###xml 437 438 437 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b003">3</xref>
###xml 680 681 680 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b004">4</xref>
###xml 809 810 809 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b005">5</xref>
###xml 811 813 811 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b013">13</xref>
###xml 841 845 841 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH,</italic>
###xml 1106 1108 1106 1108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b014">14</xref>
###xml 1109 1111 1109 1111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b018">18</xref>
###xml 1114 1117 1114 1117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 1148 1153 1148 1153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR3</italic>
###xml 1155 1160 1155 1160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1</italic>
###xml 1162 1167 1162 1167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR4</italic>
###xml 1169 1175 1169 1175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR2,</italic>
###xml 1180 1185 1180 1185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR5</italic>
###xml 1399 1404 1399 1404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR3</italic>
###xml 1409 1414 1409 1414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1</italic>
###xml 1451 1453 1451 1453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b019">19</xref>
###xml 1642 1644 1642 1644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b020">20</xref>
###xml 1700 1703 1700 1703 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 1783 1785 1783 1785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b021">21</xref>
###xml 1812 1819 <span type="species:ncbi:9606">persons</span>
Age-related macular degeneration (AMD) is the most common cause of visual disability in the elderly, and is increasing in prevalence in the Western world as the population ages. In addition to age and smoking, genetic factors play a major role in susceptibility to AMD. There is higher concordance in monozygotic than in dizygotic twins [1], and although there is rarely clear Mendelian inheritance, cases tend to cluster in families [2,3]. The search for susceptibility genes has been performed using linkage studies in AMD families, followed by family-based and case-control association studies. Chromosome 1q31 was first implicated in a linkage study involving a large family [4], and the same region was supported consistently in several genome-wide scans based on analysis of smaller multiplex families [5-13]. Several polymorphisms in CFH, the gene encoding complement factor H, were found to be strongly associated with AMD, and single nucleotide polymorphism (SNP) rs1061170, encoding a nonsynonymous change from tyrosine to histidine at codon 402, was proposed as the main determinant of disease [14-18]. CFH and the closely related genes CFHR3, CFHR1, CFHR4, CFHR2, and CFHR5 are arranged in tandem at the proximal end of a cluster of genes involved in regulation of complement activation. Recently we examined this gene cluster in detail and identified a large deletion that removed both CFHR3 and CFHR1 on a strongly protective haplotype [19].The inhibitory activity of complement factor H is controlled by binding of C-reactive protein (CRP), which increases affinity for C3b and leads to down-regulation of complement activity [20]. There are no known coding polymorphisms in the small CRP gene, but plasma CRP levels are determined by SNPs within its promoter region [21]. Of most significance in persons of European descent is the triallelic (A/C/T) SNP rs3091244, of which the C allele results in lowest plasma CRP levels and the T allele the highest.
###end p 23
###begin p 24
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b013">13</xref>
###xml 178 187 178 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
###xml 191 198 191 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PLEKHA1</italic>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b022">22</xref>
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b023">23</xref>
###xml 266 271 266 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 299 308 299 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b024">24</xref>
###xml 384 386 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b025">25</xref>
###xml 389 394 389 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 494 503 494 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
###xml 649 658 649 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
###xml 735 740 735 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 777 779 777 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b025">25</xref>
Many previous genome-wide scans also support linkage to Chromosome 10q26, with this region showing the strongest association on meta-analysis [13]. Two reports implicated either LOC387715 or PLEKHA1 as a major contributor to AMD susceptibility [22,23], and recently HTRA1 (which lies 4 kb distal to LOC387715) emerged as a leading contender for the second AMD susceptibility gene [24,25]. HTRA1 encodes a serine protease that is expressed in the retina; however, the mechanism of action of the LOC387715 gene product remains to be elucidated. The common c.205G>T nonsynonymous coding SNP (rs10490924), which changes alanine to serine at codon 69 of LOC387715, is in close linkage disequilibrium (LD) with rs11200638 in the promoter of HTRA1, which may regulate its expression [25].
###end p 24
###begin p 25
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b026">26</xref>
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b027">27</xref>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b029">29</xref>
Although earlier studies gave conflicting results, the large Beaver Dam Eye Study in 1993 showed that cigarette smoking increases the risk of exudative (or neovascular) macular degeneration [26]. Other sizeable studies have since confirmed that smoking is a risk factor in all forms of AMD [27-29].
###end p 25
###begin p 26
###xml 306 309 306 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 314 329 314 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
In contrast to most previous studies, which assessed AMD cases ranging from early to late stages of disease, we restricted our cases to those with the blinding neovascular form of AMD in one or both eyes, and compared them to controls with no sign of macular disease. We aimed to refine the association of CFH and LOC387715/HTRA1 with neovascular AMD and to form a model of AMD risk based on inherited variation in these genes in conjunction with smoking status.
###end p 26
###begin title 27
Methods
###end title 27
###begin title 28
Study Population and Diagnostic Criteria
###end title 28
###begin p 29
###xml 7 8 7 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 334 335 334 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 391 392 391 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 615 616 615 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 476 488 <span type="species:ncbi:9606">participants</span>
Cases (n = 401) with choroidal neovascularisation due to AMD in at least one eye were recruited from ophthalmology clinics in the Royal Victoria Hospital, Belfast, UK, which is the regional referral centre for Northern Ireland. Cases were recruited opportunistically during two intervals, the first between June 2002 and August 2003 (n = 305) and the second between June and September 2006 (n = 96). Of those invited to participate, 98% agreed. Prior to approaching potential participants, the diagnosis of neovascular AMD was confirmed by clinical examination followed by fluorescein angiography. A control group (n = 266) was recruited through random sampling of older adults (aged 65 y and above) from a population-based register, with no exclusion criteria. In this sample the participation rate was approximately50%; those who refused to participate were more likely to be older and female.
###end p 29
###begin p 30
###xml 742 744 742 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b030">30</xref>
###xml 859 861 859 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b031">31</xref>
###xml 436 448 <span type="species:ncbi:9606">participants</span>
###xml 667 679 <span type="species:ncbi:9606">participants</span>
Stereoscopic digital fundus photographs were captured at the time of examination, and images were sent to the photographic reading centre for grading using the definitions of the Wisconsin Age Related Maculopathy Grading System. Fundi of controls were free of any drusen, or had fewer than five hard drusen of diameter less than 63 microns. They had no focal pigmentary irregularities (i.e., hyperpigmentation or hypopigmentation). All participants were from Northern Ireland and described themselves as of European descent. Current smoking status and smoking history were obtained through the use of a questionnaire previously validated in the Whitehall study, with participants classified into never smokers, ex-smokers or current smokers [30]. Smoking prevalence data for the UK population in 1974 and 2003 were obtained from the General Household Survey [31], UK Office for National Statistics.
###end p 30
###begin p 31
###xml 66 73 66 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040355-sd001">Text S1</xref>
###xml 170 177 170 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040355-sd002">Text S2</xref>
Informed written consent was obtained from all subjects involved (Text S1). Our study was approved by the Research Ethics Committee of the Queen's University of Belfast (Text S2).
###end p 31
###begin title 32
Genotyping
###end title 32
###begin p 33
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b032">32</xref>
###xml 490 493 490 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 498 507 498 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
###xml 540 543 540 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 748 757 748 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
###xml 870 879 870 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
###xml 899 904 899 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 920 923 920 923 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 1022 1025 1022 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 1124 1125 1124 1125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 1188 1203 1188 1203 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
###xml 1255 1256 1255 1256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 1266 1267 1266 1267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 1267 1268 1267 1268 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1309 1311 1309 1311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b033">33</xref>
DNA was extracted from peripheral blood leucocytes or frozen buffy coat samples using standard protocols. High-throughput SNP genotyping was outsourced and based on Illumina bead technology (Illumina, San Diego, United States), supplemented in-house with multiplex PCR and primer extension methodology (ABI Snapshot). Rs11200638 was typed by sequencing. All primer sequences are available from AEH. Genotype data were entered in linkage format into Haploview [32] for automated analysis of CFH and LOC387715 haplotypes. Scoring risk at the CFH-related cluster was based on haplotypes of SNPs rs6677604, rs3753396, rs419137, and rs2284664. Nonsynonymous coding SNPs rs1061170 (Y402H) and rs800292 (I62V) were also typed. The three SNPs typed within LOC387715 (rs10490923, rs2736911, and rs10490924) tagged four common haplotypes of a haplotype block that extended across LOC387715 to the promoter of HTRA1. Genotyping of CRP markers rs3091244 and rs1205 was restricted to a subgroup of 170 cases and 170 controls, and four CRP haplotypes were assessed. All markers within each of the above haplotypes showed complete LD with D' = 1, therefore haplotypes could be assigned with confidence. LOC387715/HTRA1 haplotypes consisted of rs10490924 and rs11200638 (D' = 0.98; r2 = 0.93), and were assigned using PHASE [33].
###end p 33
###begin title 34
Statistical Analysis
###end title 34
###begin p 35
###xml 222 225 222 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 615 624 615 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
###xml 629 644 629 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
###xml 1215 1218 1215 1218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 1223 1238 1223 1238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
###xml 1423 1426 1423 1426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 1428 1443 1428 1443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
###xml 1751 1759 1751 1759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040355-st001">Table S1</xref>
The statistical analyses and model building were preplanned before collection of genotype data. Allele frequency differences in cases and controls were assessed by performing Pearson's Chi-square test of association. Each CFH haplotype was entered into the logistic regression model as a count (0, 1, or 2) depending on the number of copies of the haplotype an individual carried. To avoid collinearity problems the lowest risk haplotype was omitted from the model so that odds ratios (ORs) were measured relative to homozygote carriers of this haplotype. An exception to this approach was made for analysis of the LOC387715 and LOC387715/HTRA1 region where increased risk of AMD was confined to one haplotype, with a much higher risk in homozygote carriers than predicted by the multiplicative model. For our final risk analysis, the number of copies carried of this detrimental haplotype were coded 0, 1, or 2. Tests for deviation from the multiplicative genetic model and for interactions between genetic risk factors and smoking were obtained using likelihood ratio Chi-squared tests. The fitted logistic model produced ORs that were converted to predicted probabilities of AMD for each possible combination of CFH and LOC387715/HTRA1 haplotypes and smoking status. Conversion was performed using an estimated prevalence of severe AMD of 3% and known frequencies for haplotypes and smoking status, and by assuming that CFH, LOC387715/HTRA1, and smoking were independently distributed in the UK population. These predicted probabilities were used to sort the combinations in order of increasing predicted AMD risk and then to divide the population into approximate tenths of predicted AMD risk. More detailed statistical information is provided in Table S1.
###end p 35
###begin title 36
Results
###end title 36
###begin title 37
###xml 0 11 <span type="species:ncbi:9606">Participant</span>
Participant Population
###end title 37
###begin p 38
###xml 223 231 223 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040355-st002">Table S2</xref>
###xml 23 31 <span type="species:ncbi:9606">patients</span>
Our study involved 401 patients with end-stage neovascular AMD in at least one eye and 266 age-matched controls with healthy fundi. There was a slight preponderance of females in each group, as expected for this age group (Table S2). Mean age at examination was in the mid-seventies for each group (cases 75.6 years; controls 75.8 years), with individuals ranging in age from 54 to 98 y in the case group and from 66 to 100 y in the control group.
###end p 38
###begin title 39
###xml 4 7 4 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
The CFH Region Associates with AMD
###end title 39
###begin p 40
###xml 43 54 43 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH, CFHR3,</italic>
###xml 59 64 59 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1</italic>
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b019">19</xref>
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b034">34</xref>
###xml 285 287 285 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D&#8242;</italic>
###xml 463 467 463 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH,</italic>
###xml 730 735 730 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR3</italic>
###xml 740 745 740 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1</italic>
Our analysis of the haplotype structure of CFH, CFHR3, and CFHR1 has been reported elsewhere [19] and was supported by final HapMap data [34]. There was complete LD within each block, and a strong spine of LD between the three large haplotype blocks covering these genes (multiallelic D' = 0.89 between blocks 1 and 2, and 0.91 between blocks 2 and 3). We typed the five common haplotypes of the second block, which encompassed exon 11 to the end of intron 17 of CFH, tagged by SNPs rs6677604, rs3753396, rs419137, and rs2284664. Three haplotypes (1:GACG, 2:GAAG, and 3:GGAG) were associated with increased risk and two (4:GAAA and 5:AAAG) were protective of AMD. The most protective (haplotype 5) was associated with deletion of CFHR3 and CFHR1 from block 3.
###end p 40
###begin title 41
###xml 4 13 4 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
The LOC387715/HTRA1 Region Associates with AMD
###end title 41
###begin p 42
###xml 36 45 36 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
###xml 401 406 401 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 455 456 455 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 466 467 466 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 467 468 467 468 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 502 511 502 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
###xml 644 653 644 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
###xml 667 675 667 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040355-st002">Table S2</xref>
###xml 710 725 710 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
###xml 1077 1092 1077 1092 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
###xml 1197 1205 1197 1205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040355-st003">Table S3</xref>
###xml 1224 1239 1224 1239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
###xml 1333 1336 1333 1336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 1341 1356 1341 1356 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
###xml 1415 1423 1415 1423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040355-st004">Table S4</xref>
The extremely strong association of LOC387715 on Chromosome 10 with AMD was confirmed by genotyping SNPs rs10490923, rs2736911, and rs10490924. These SNPs were in complete LD and four haplotypes were identified. Of most importance was rs10490924, with the risk allele (T) being found only on haplotype 2, and present on 48.9% of AMD and 20.5% of control chromosomes. SNP rs11200638 in the promoter of HTRA1 was typed and found to be in extremely high LD (D' = 0.98; r2 = 0.93) with rs10490924 and with LOC387715 haplotypes, with the risk allele (A; 47.9% of AMD and 19.4% of control chromosomes) closely associated with rs10490924 allele T and LOC387715 haplotype 2 (Table S2). All four possible haplotypes of LOC387715/HTRA1 that combined rs10490924 and rs11200638 were found (1:GG, 2:TA, 3:TG, 4:GA), although haplotypes 3 and 4 were exceedingly rare, totalling 1.6% of all chromosomes. These rare haplotypes were distributed similarly through cases and controls and were merged with haplotype 1 for all further analyses. Based on simple counts of alleles or haplotypes, the LOC387715/HTRA1 haplotype provided marginally better predictive value than either of the constituent SNPs individually (Table S3). The detrimental LOC387715/HTRA1 haplotype 2 was present on 47.0% of AMD and 18.2% of control chromosomes. Haplotype data for CFH and LOC387715/HTRA1 and smoking status of our cases and controls are shown in Table S4.
###end p 42
###begin title 43
###xml 18 21 18 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
No Association of CRP with AMD
###end title 43
###begin p 44
###xml 56 59 56 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b021">21</xref>
###xml 437 438 437 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 557 566 557 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
###xml 663 666 663 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 681 684 681 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
The triallelic SNP rs3091244 within the promoter of the CRP gene (which affects plasma levels of CRP) was typed, and rs1205 was also assessed to increase haplotype informativeness for this gene. Four haplotypes were identified. The rarest haplotype (4:AC, associated with high CRP plasma level [21]) was more prevalent in cases; however, the overall haplotype distribution in cases and controls failed to reach statistical significance (p = 0.06), and using conventional logistic regression the weak association was attenuated by adjustment for carriage of LOC387715 haplotype 2 and smoking. There was only weak and nonsignificant evidence of interaction between CFH haplotype and CRP genotype.
###end p 44
###begin title 45
Association with Smoking
###end title 45
###begin p 46
###xml 22 23 22 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 66 67 66 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 128 131 128 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 136 145 136 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
###xml 214 229 214 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
###xml 241 242 241 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 275 278 275 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 290 291 290 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 312 315 312 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 320 335 320 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
###xml 348 349 348 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
As expected, smoking (p < 0.001) and previous history of smoking (p = 0.05) were associated with disease status, independent of CFH and LOC387715 haplotype. There was no evidence of interaction between smoking and LOC387715/HTRA1 haplotype (p = 0.42), or between smoking and CFH haplotype (p = 0.07), or between CFH and LOC387715/HTRA1 haplotypes (p = 0.42). Smoking history in the controls correlated closely with the data from the UK General Household Survey with 54% and 55% never smokers, respectively; however, this group contained slightly fewer smokers (12% versus 17%) and more ex-smokers than in the general population.
###end p 46
###begin title 47
Logistic Regression Analyses
###end title 47
###begin p 48
###xml 72 75 72 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 80 95 80 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
###xml 149 152 149 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 365 372 365 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040355-t001">Table 1</xref>
###xml 471 474 471 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 476 478 476 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b019">19</xref>
###xml 498 501 498 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 782 797 782 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
###xml 856 859 856 859 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 920 935 920 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
###xml 1060 1067 1060 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040355-t002">Table 2</xref>
###xml 1263 1270 1263 1270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040355-t003">Table 3</xref>
Logistic regression analysis was performed to examine the effect of the CFH and LOC387715/HTRA1 haplotypes carried and smoking status on AMD. At the CFH locus, haplotype 5 conferred the lowest risk, with haplotype 4 also being protective. Haplotype 2 remained the most detrimental, with carriage increasing the risk of AMD more than 4-fold relative to haplotype 5 (Table 1). Two nonsynonymous coding SNPs, rs1061170 (Y402H) and rs800292 (I62V), located within block 1 of CFH [19], were also typed. CFH block 2 haplotypes 1 and 2 were strongly associated with the high-risk allele C of rs1061170 (402H), with the T allele associated with haplotypes 3, 4, and 5. The low-risk A allele of rs800292 (I62) was associated uniquely with haplotype 4. The detrimental effect of variation at LOC387715/HTRA1 on AMD phenotype was mediated through haplotype 2. Unlike CFH, there was not a multiplicative effect with carriage of two LOC387715/HTRA1 risk haplotypes. A single copy of haplotype 2 increased the risk of AMD nearly 3-fold relative to the haplotype 1 baseline (Table 2); however, homozygotes for haplotype 2 had their risk greatly elevated by a factor of 33. Past and present smokers showed a graded increase in risk of AMD compared to those who had never smoked (Table 3).
###end p 48
###begin p 49
###xml 33 36 33 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 99 114 99 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
Effect of Haplotype Variation in CFH on AMD by Simultaneous Logistic Regression Analysis Including LOC387715/HTRA1 and Smoking Status
###end p 49
###begin p 50
###xml 33 48 33 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
###xml 111 114 111 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
Effect of Haplotype Variation in LOC387715/HTRA1 on AMD by Simultaneous Logistic Regression Analysis Including CFH and Smoking Status
###end p 50
###begin p 51
###xml 87 90 87 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 95 104 95 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
###xml 105 110 105 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
Effect of Smoking Status on AMD by Simultaneous Logistic Regression Analysis Including CFH and LOC387715/HTRA1
###end p 51
###begin title 52
AMD Risk Scoring System
###end title 52
###begin p 53
###xml 154 157 154 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 162 177 162 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
A simple multifactorial AMD risk-scoring system for each individual was developed by multiplying the ORs for genetic effects of each carried haplotype of CFH and LOC387715/HTRA1, and smoking status.
###end p 53
###begin p 54
The overall theoretical distribution of risk for the European-descent population was estimated from haplotype frequencies (derived from reported frequency data available from large studies for the polymorphisms that constituted each haplotype, which did not differ significantly from frequencies found in our control group) combined with UK smoking data since 1974, which classified 55% of our present-aged population as never smokers, 28% as ex-smokers, and 17% as current smokers. This population distribution was split by deciles into ten risk groups for further analysis.
###end p 54
###begin p 55
###xml 247 255 247 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040355-g001">Figure 1</xref>
###xml 384 392 384 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040355-g002">Figure 2</xref>
As expected, our controls with no sign of macular disease were biased marginally (and nonsignificantly) in the supernormal direction, with slight clustering in the lower-risk groups, whereas our AMD cases fell predominantly into high-risk groups (Figure 1). The risk of developing end-stage AMD in at least one eye in advancing years can be predicted from an individual's risk score (Figure 2). Those with scores falling within the lowest-risk groups have minimal risk of developing AMD. The overall population prevalence of 3% was exceeded only in the two highest-risk groups, and AMD risk rose steeply to 15.5% for those in the highest tenth of the population.
###end p 55
###begin title 56
###xml 90 97 <span type="species:ncbi:9606">Persons</span>
Distribution of AMD Cases and Controls According to Predicted Risk Group Estimated for UK Persons of European Descent
###end title 56
###begin p 57
The percentages of AMD cases and controls within each risk group are shown.
###end p 57
###begin title 58
Risk of Developing AMD According to Risk Group in the UK European-Descent Population under the Prevailing Smoking Profile, and if None of the Population Had Ever Smoked
###end title 58
###begin p 59
###xml 83 98 83 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
###xml 129 132 129 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 403 411 403 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040355-g003">Figure 3</xref>
###xml 413 414 413 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 451 452 451 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 548 549 546 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 587 588 585 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 743 746 739 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 793 808 789 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
###xml 610 618 <span type="species:ncbi:9606">patients</span>
Overall, genetic factors contributed more than smoking status to risk of AMD, with LOC387715/HTRA1 proving more influential than CFH. The smoking element of the AMD risk score was elevated in our cases compared to controls. Age of onset of neovascular disease in the first eye was known for 296 of the AMD cases. Those who smoked showed earlier onset of end-stage disease than did former or nonsmokers (Figure 3; F = 9.81, degrees of freedom = 2,284; p </= 0.001). There was a similar significant trend to earlier onset with increasing risk group (F = 11.97, degrees of freedom = 1,277; p </= 0.001). When AMD patients were separated into two equal groups based on age of end-stage disease in the first eye, there was an increased effect from CFH and smoking in the earlier-onset group and of LOC387715/HTRA1 in the later-onset group (unpublished data).
###end p 59
###begin title 60
Age of End-Stage AMD According to Smoking Status
###end title 60
###begin p 61
Shown are means +/- 95% confidence intervals of each group.
###end p 61
###begin title 62
Discussion
###end title 62
###begin p 63
###xml 49 52 49 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 57 72 57 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
###xml 384 387 384 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 392 407 392 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
Our study assessed the influence of genes in the CFH and LOC387715/HTRA1 regions and smoking status on the etiology of neovascular AMD. We developed a risk model for disease based on comprehensive haplotyping of the genes followed by analysis using logistic regression that also included smoking status. Our model is the first that we know of to take account of haplotypes within the CFH and LOC387715/HTRA1 regions, and allows early identification of those at high risk of developing neovascular AMD in old age. AMD was not inevitable for those in the highest-risk categories, hence exposure to a trigger may be necessary for development of disease.
###end p 63
###begin p 64
###xml 1047 1049 1047 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b013">13</xref>
###xml 1120 1123 1120 1123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 1141 1164 1141 1164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/PLEKHA1/HTRA1</italic>
###xml 883 890 <span type="species:ncbi:9606">patient</span>
AMD is one of the most common multifactorial diseases of the elderly. For several years, genes have been thought to play a role in susceptibility. The model generally applied to such complex disorders has been of multiple genes each contributing a small effect to overall risk, in conjunction with environmental factors. This model has been further complicated by the possibility of genes acting with either dominant or negative effects, of gene-gene or gene-environment interactions, and of genetic heterogeneity in which mutations in different genes may have a major influence in different individuals. As is often the case in clinical genetics, a much more straightforward pattern emerges when the possibilities are investigated and some ruled out. Credit must be given to the firm scientific base provided by well-designed linkage studies of families with more than one affected patient from which AMD susceptibility loci have been identified. Although individual studies often identified linkages that have not been confirmed, meta-analyses [13] clearly revealed the regions of Chromosomes 1 and 10 (from which the CFH gene cluster and LOC387715/PLEKHA1/HTRA1 have recently emerged) as major susceptibility loci for all forms of AMD. It is increasingly likely that the genetic component of AMD should be viewed as oligogenic rather than polygenic.
###end p 64
###begin p 65
###xml 4 7 4 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 266 269 266 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 428 431 428 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 433 438 433 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR3</italic>
###xml 444 449 444 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1</italic>
###xml 551 553 551 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b019">19</xref>
###xml 1150 1153 1150 1153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 1942 1947 1942 1947 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1</italic>
###xml 1952 1957 1952 1957 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR3</italic>
###xml 2021 2023 2021 2023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b019">19</xref>
The CFH gene cluster comprises five related genes that are all expressed. These genes share a very high level of homology arising from gene duplication, and care must be taken in typing and identifying polymorphic variants at the C-terminal region of CFH and in the CFH-related genes. We chose to score risk on the basis of five haplotypes of the most central block, which was in strong LD with the adjacent haplotype blocks in CFH, CFHR3, and CFHR1. Our earlier studies showed strong association between AMD and markers extending across this region [19]. Any coding variants or polymorphisms regulating splicing or expression of these genes may affect risk, and may be based within different haplotype blocks. We also typed Y402H and I62V, but analysis of these common coding polymorphisms did not confer additional information affecting AMD risk. Other studies have limited their analysis to the effect of Y402H, which has been regarded as the main determinant of disease, but this analysis gives an incomplete and inaccurate representation of the region. Only haplotype analysis can assess the effect of combinations of all the coding variants in CFH that may contribute to AMD susceptibility. The C allele of rs1061170, which types histidine at codon 402 within the first haplotype block, is associated with a haplotype conferring high risk of AMD, and is coupled with our haplotypes 1 and 2 in the second haplotype block. It is also in complete LD with several other SNPs, one of which has the potential to create a novel splice site and to introduce a new exon containing a premature stop codon. This variant would be expected to result in nonsense-mediated decay of the transcript and reduced CFH levels. Despite being associated with the T allele of rs1061170, haplotype 3 is only marginally less severe in risk than haplotype 1. Haplotypes 4 and 5 are relatively protective. We previously identified a deletion of 85 kb encompassing CFHR1 and CFHR3, which plausibly confers the protective effect of haplotype 5 [19]. The coding variant most strongly associated with haplotype 4 may be the A allele of rs800292, which encodes I62, though this represents a conservative amino acid change. Further work is needed to clarify the molecular bases of the haplotypic effects.
###end p 65
###begin p 66
###xml 158 167 158 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b023">23</xref>
###xml 301 308 301 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PLEKHA1</italic>
###xml 312 317 312 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 342 347 342 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 478 487 478 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
###xml 529 534 529 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 597 602 597 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 608 617 608 617 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
###xml 720 722 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b023">23</xref>
###xml 822 831 822 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
###xml 839 844 839 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 874 877 874 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 910 925 910 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
###xml 1238 1247 1238 1247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
###xml 1271 1276 1271 1276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
###xml 1360 1369 1360 1369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
###xml 1377 1382 1377 1382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
Much interest surrounds the identity of the AMD susceptibility locus on Chromosome 10. Very strong data focus on the protein encoded by the hypothetical gene LOC387715, with the alanine-to-serine polymorphism detected by rs10490924 as the most probable causative variant [23]. Alternatives are either PLEKHA1 or HTRA1, which flank the locus; HTRA1, which encodes a serine protease, is the more attractive on functional grounds. Another possibility is that the putative exons of LOC387715 or additional open reading frames in the HTRA1 promoter region may be included in alternative transcripts of HTRA1. The LOC387715 transcript is exceedingly rare, but has been reported to be present at very low levels in the retina [23]. The markers we typed for this locus identified all common haplotypes of a block that encompassed LOC387715 to the HTRA1 promoter. In contrast to the CFH gene cluster, the effect of the LOC387715/HTRA1 region on AMD susceptibility appeared to be mediated through a single detrimental haplotype, with all others being generally protective. In addition to carrying the rare coding variant of rs10490924, the detrimental haplotype was also very strongly associated with several variants in the untranslated region of LOC387715 and in the promoter of HTRA1, and we cannot at present discriminate between the relative merits of variation in LOC387715 or the HTRA1 promoter as effectors of AMD susceptibility at this locus.
###end p 66
###begin p 67
###xml 397 406 397 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b035">35</xref>
###xml 423 425 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b036">36</xref>
###xml 547 550 547 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 555 558 555 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
###xml 560 562 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b037">37</xref>
###xml 585 588 585 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 650 652 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b038">38</xref>
###xml 659 662 659 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 697 702 697 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC6</italic>
###xml 704 706 704 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b039">39</xref>
Further genetic or environmental factors, or their interactions, may be found to affect AMD risk. These factors should be assessed for effect using a regression model that includes all proven genetic and environmental factors, rather than in isolation. Initial reports are prone to inflation to some extent by type 1 error. Conflicting data have been reported about a possible interaction between LOC387715 and smoking [35,36]. Our evidence does not support an interaction, and we find limited support for an interaction recently reported between CFH and CRP [37]. Interaction between CFH and the genes encoding complement C2 or complement factor B [38], and CFH and an excision repair gene named ERCC6 [39] await confirmation.
###end p 67
###begin p 68
###xml 1075 1090 1075 1090 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
###xml 1095 1098 1095 1098 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 1028 1036 <span type="species:ncbi:9606">patients</span>
Options for reducing the future burden of AMD appear as our knowledge increases. Although smoking status is of less importance than the two main genetic factors, it is a relatively straightforward risk to target in individuals with high genetic load. Our data show that if none of our population had smoked, there would have been an overall reduction of 33% in AMD today. Our current and ex-smokers lost vision at an earlier age, so it is probable that our calculations underestimate the benefit to the population from nonsmoking. We did not assess the importance of smoking on earlier stages of AMD; however, delaying either onset of disease or advancement to the blinding end-stage by 5-10 y would have a major impact on prevalence of blindness. It is now possible to identify those at high genetic risk for whom smoking is particularly unwise. In the past, smokers have been prepared to ignore greatly increased risks of lung cancer and other smoking-related diseases, but attitudes to smoking are changing. Relatives of AMD patients are more likely to carry an excess of LOC387715/HTRA1 and CFH-related genetic risk factors. Those who are shown to be at high risk, with relatives who have lost their vision, may be more prepared to heed advice to refrain from smoking than the general population.
###end p 68
###begin p 69
###xml 241 246 241 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1</italic>
###xml 251 256 251 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR3</italic>
###xml 266 269 266 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
Gene therapy to repair genetic defects is still in the experimental phase and is largely unproven. Of great promise are methods aimed at gene silencing by degradation of RNA using short interfering double-stranded RNA molecules. Deletion of CFHR1 and CFHR3 from the CFH-related gene cluster is strongly protective against AMD, hence these genes make excellent targets for silencing in future studies aimed at reducing the burden of disease.
###end p 69
###begin title 70
Study Limitations
###end title 70
###begin p 71
###xml 676 679 676 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 727 729 727 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040355-b040">40</xref>
We assessed the genetic factors and smoking history, which are generally accepted as conferring high population-attributable risk for AMD. The model we developed to estimate risk of neovascular AMD best fits our data, and it is important that it should be validated in independent datasets of similar phenotypes. It is possible that rare variants in other genes may be found to be highly influential in a small proportion of the population, and may cause AMD in a few individuals predicted to be at low risk using our present model. Genes with a modifying effect on AMD risk may also be identified. In either case, our model for prediction of AMD risk may be modified easily. CFH may also affect risk of myocardial infarction [40], and we made no attempt to adjust for this condition or for smoking-related diseases that affect longevity.
###end p 71
###begin title 72
Supporting Information
###end title 72
###begin title 73
Supplementary Statistical Data
###end title 73
###begin p 74
(34 KB DOC)
###end p 74
###begin p 75
Click here for additional data file.
###end p 75
###begin title 76
Combinations of Genotypes at rs10490924 and rs11200638
###end title 76
###begin p 77
(25 KB DOC)
###end p 77
###begin p 78
Click here for additional data file.
###end p 78
###begin title 79
###xml 55 70 55 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715/HTRA1</italic>
Comparison of rs11200638, rs10490924, and the Combined LOC387715/HTRA1 Haplotype of These Markers
###end title 79
###begin p 80
Analysis is based on allele or haplotype counting and does not account for the nonadditive effect at this locus.
###end p 80
###begin p 81
(28 KB DOC)
###end p 81
###begin p 82
Click here for additional data file.
###end p 82
###begin title 83
###xml 62 63 62 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 85 86 85 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
Summary of Gender, Smoking, and Haplotype Data for AMD Cases (n = 401) and Controls (n = 266)
###end title 83
###begin p 84
(44 KB DOC)
###end p 84
###begin p 85
Click here for additional data file.
###end p 85
###begin title 86
Consent Form
###end title 86
###begin p 87
(24 KB DOC)
###end p 87
###begin p 88
Click here for additional data file.
###end p 88
###begin title 89
Ethical Agreement
###end title 89
###begin p 90
(276 KB TIFF)
###end p 90
###begin p 91
Click here for additional data file.
###end p 91
###begin p 92
We thank David McGibbon for assistance with DNA extraction.
###end p 92
###begin title 93
Abbreviations
###end title 93
###begin p 94
age-related macular degeneration
###end p 94
###begin p 95
complement factor H
###end p 95
###begin p 96
confidence interval
###end p 96
###begin p 97
C-reactive protein
###end p 97
###begin p 98
linkage disequilibrium
###end p 98
###begin p 99
odds ratio
###end p 99
###begin p 100
single nucleotide polymorphism
###end p 100
###begin title 101
References
###end title 101
###begin article-title 102
A twin study of age-related macular degeneration
###end article-title 102
###begin article-title 103
Is genetic predisposition an important risk factor in age-related macular degeneration?
###end article-title 103
###begin article-title 104
Familial aggregation of age-related maculopathy
###end article-title 104
###begin article-title 105
Age-related macular degeneration. Clinical features in a large family and linkage to chromosome 1q
###end article-title 105
###begin article-title 106
A full genome scan for age-related maculopathy
###end article-title 106
###begin article-title 107
Age-related maculopathy: an expanded genome-wide scan with evidence of susceptibility loci within the 1q31 and 17q25 regions
###end article-title 107
###begin article-title 108
A whole-genome screen of a quantitative trait of age-related maculopathy in sibships from the Beaver Dam Eye Study
###end article-title 108
###begin article-title 109
Age-related macular degeneration-a genome scan in extended families
###end article-title 109
###begin article-title 110
A genomewide scan for age-related macular degeneration provides evidence for linkage to several chromosomal regions
###end article-title 110
###begin article-title 111
Dissection of genomewide-scan data in extended families reveals a major locus and oligogenic susceptibility for age-related macular degeneration
###end article-title 111
###begin article-title 112
Age-related macular degeneration: a high-resolution genome scan for susceptibility loci in a population enriched for late-stage disease
###end article-title 112
###begin article-title 113
Linkage analysis for age-related macular degeneration supports a gene on chromosome 10q26
###end article-title 113
###begin article-title 114
Meta-analysis of genome scans of age-related macular degeneration
###end article-title 114
###begin article-title 115
Complement factor H polymorphism in age-related macular degeneration
###end article-title 115
###begin article-title 116
Complement factor H variant increases the risk of age-related macular degeneration
###end article-title 116
###begin article-title 117
Complement factor H polymorphism and age-related macular degeneration
###end article-title 117
###begin article-title 118
Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration
###end article-title 118
###begin article-title 119
###xml 63 70 63 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HF1/CFH</italic>
A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration
###end article-title 119
###begin article-title 120
###xml 9 12 9 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR1</italic>
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFHR3</italic>
A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration
###end article-title 120
###begin article-title 121
C-reactive protein inhibits pneumococcal activation of the alternative pathway by increasing the interaction between factor H and C3b
###end article-title 121
###begin article-title 122
###xml 45 48 45 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRP</italic>
Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels
###end article-title 122
###begin article-title 123
Susceptibility genes for age-related maculopathy on chromosome 10q26
###end article-title 123
###begin article-title 124
###xml 13 22 13 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk
###end article-title 124
###begin article-title 125
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
HTRA1 promoter polymorphism in wet age-related macular degeneration
###end article-title 125
###begin article-title 126
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HTRA1</italic>
A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration
###end article-title 126
###begin article-title 127
The Beaver Dam Eye Study: the relation of age-related maculopathy to smoking
###end article-title 127
###begin article-title 128
Smoking and age-related maculopathy. The Blue Mountains Eye Study
###end article-title 128
###begin article-title 129
The prevalence of age-related maculopathy by geographic region and ethnicity. The Colorado-Wisconsin Study of Age-Related Maculopathy
###end article-title 129
###begin article-title 130
###xml 68 75 <span type="species:ncbi:9606">persons</span>
Smoking is also associated with age-related macular degeneration in persons aged 85 years and older: The Rotterdam Study
###end article-title 130
###begin article-title 131
Smoking and other risk factors for coronary heart disease
###end article-title 131
###begin article-title 132
Haploview: analysis and visualization of LD and haplotype maps
###end article-title 132
###begin article-title 133
A comparison of Bayesian methods for haplotype reconstruction from population genotype data
###end article-title 133
###begin article-title 134
###xml 55 64 55 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
Cigarette smoking strongly modifies the association of LOC387715 and age-related macular degeneration
###end article-title 134
###begin article-title 135
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CFH</italic>
###xml 5 11 5 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ELOVL4</italic>
###xml 13 20 13 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PLEKHA1</italic>
###xml 25 34 25 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LOC387715</italic>
CFH, ELOVL4, PLEKHA1 and LOC387715 genes and susceptibility to age-related maculopathy: AREDS and CHS cohorts and meta-analyses
###end article-title 135
###begin article-title 136
Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration
###end article-title 136
###begin article-title 137
###xml 23 25 23 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BF</italic>
###xml 55 57 55 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C2</italic>
Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration
###end article-title 137
###begin article-title 138
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERCC6</italic>
Synergic effect of polymorphisms in ERCC6 5' flanking region and complement factor H on age-related macular degeneration predisposition
###end article-title 138
###begin article-title 139
A common polymorphism in the complement factor H gene is associated with increased risk of myocardial infarction: the Rotterdam Study
###end article-title 139
###begin p 140
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
###xml 426 434 <span type="species:ncbi:9606">patients</span>
###xml 500 507 <span type="species:ncbi:9606">patient</span>
###xml 600 608 <span type="species:ncbi:9606">patients</span>
Author contributions. AEH was the principal investigator of this study, had full access to all of the data, and takes responsibility for the integrity of the data and the accuracy of the data analysis and for the decision to submit this paper for publication. NO and HE assisted in the design and NO also assisted in implementation and data analysis. CP performed logistic regression and further statistical analysis. All AMD patients were under the supervision of GS and UC, who phenotyped and took patient samples and smoking history with the assistance of VMcC. RH provided smoking status of some patients and assisted with extraction of DNA. AEH wrote the manuscript, which has been approved by all authors.
###end p 140
###begin p 141
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding:</bold>
Funding: This study was part funded by a grant from PPP Healthcare (now The Health Foundation). UC and RH were supported by Evigenoret. The funders played no part in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.
###end p 141
###begin p 142
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests:</bold>
Competing Interests: Queen's University Belfast holds a patent titled "Protection against and treatment of Age-Related Macular Degeneration."
###end p 142

